Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), reported selling 17,884 shares of Arteris common stock on January 15, 2026 at a weighted average price of $17.8357 per share. The trades were executed in multiple transactions at prices ranging from $17.75 to $18.04 and were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025.
Following this sale, Bayview Legacy, LLC reported beneficial ownership of 9,399,071 Arteris shares held indirectly. K. Charles Janac is the manager of Bayview Legacy, LLC and is deemed to have voting and dispositive power over these shares, and he has separately filed his own Form 4 for the same transaction.
Arteris, Inc. insider activity shows a small planned share sale by an entity managed by its President and CEO, Charles K. Janac. On 01/13/2026, Bayview Legacy, LLC, over which Janac has voting and dispositive power, sold 2,116 shares of Arteris common stock at a weighted average price of $17.7901 per share under a Rule 10b5-1 trading plan adopted on March 5, 2025. Following this transaction, Bayview Legacy, LLC held 9,416,955 shares indirectly for Janac, while he also held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), reported an open-market sale of 2,116 shares of Arteris common stock on January 13, 2026. The shares were sold at a weighted average price of $17.7901 per share, in multiple trades between $17.7500 and $17.8100. The transaction was made under a Rule 10b5-1 trading plan adopted on March 5, 2025, meaning the sales followed a pre-set schedule. After this sale, Bayview Legacy, LLC indirectly beneficially owned 9,416,955 shares, and its manager, K. Charles Janac, is deemed to have voting and dispositive power over those shares.
Arteris, Inc. (AIP) President and CEO Charles Janac, a director and 10% owner, reported an automatic sale of common stock made under a pre-arranged Rule 10b5-1 trading plan. On January 8, 2026, Bayview Legacy, LLC, an entity managed by Janac, sold 50,000 shares of Arteris common stock at a weighted average price of $16.5831 per share, with individual sale prices ranging from $16.2150 to $17.3600.
Following this transaction, 9,419,071 shares of Arteris common stock were beneficially owned indirectly through Bayview Legacy, LLC. Janac also held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.
Arteris, Inc. reported an insider share sale by Bayview Legacy, LLC, a 10% owner of the company. On January 8, 2026, Bayview Legacy, LLC sold 50,000 shares of Arteris common stock at a weighted average price of $16.5831 per share in open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. After this sale, Bayview Legacy, LLC beneficially owned 9,419,071 shares indirectly. K. Charles Janac is the manager of Bayview Legacy, LLC and is deemed to have voting and dispositive power over these shares, and he has separately filed his own Form 4 for the same transaction.
Arteris, Inc. reported that its VP and Chief Financial Officer, Nicholas B. Hawkins, sold 5,836 shares of common stock on January 7, 2026. The shares were sold under a pre-arranged Rule 10b5-1 trading plan that he adopted on June 4, 2025.
The sale was executed at a weighted average price of $17.272 per share, with individual trades occurring between $16.95 and $17.44. Following this transaction, Hawkins beneficially owns 82,267 shares of Arteris common stock, which includes 144 shares acquired on November 21, 2025 through the company’s Employee Stock Purchase Plan.
Arteris, Inc. insider trading report: President and CEO Charles Janac, who is also a director and 10% owner of Arteris, reported selling 11,145 shares of common stock on 01/06/2026 at a weighted average price of $16.9032 per share, in transactions executed between $15.86 and $17.65. The sale was made under a Rule 10b5-1 trading plan adopted on March 5, 2025.
After this sale, Janac directly beneficially owned 139,487 Arteris shares. He also had indirect beneficial ownership of 9,469,071 shares held by Bayview Legacy, LLC, where he is the manager and has voting and dispositive power, and 56,252 shares held by the Charles and Lydia Janac Trust, for which he serves as trustee.
Arteris, Inc. Chief Operating Officer Moll Laurent R reported a small insider sale of common stock. On January 6, 2026, the executive sold 1,420 shares at a price of $16.23 per share. After this transaction, Moll Laurent R directly held 250,573 shares of Arteris common stock. The sale was made under a Rule 10b5-1 trading plan that the reporting person adopted on March 12, 2025, indicating it was pre-arranged rather than a discretionary market-timed trade.
Form 144 reports a planned sale of 150,000 common shares of the issuer’s stock through Morgan Stanley Smith Barney LLC on or about 01/08/2026, to be traded on NASDAQ. The shares to be sold have an indicated aggregate market value of 2,613,000.00, and the issuer has 43,683,773 shares outstanding.
The seller acquired these 150,000 common shares on 11/05/2013 in a private acquisition from the issuer, paid in cash. The filing also lists sales during the past three months, including 10b5-1 sales for K. Charles Janac and Bayview Legacy, LLC, such as 70,000 shares sold on 12/08/2025 for 1,239,964.00 and 50,000 shares sold on 11/10/2025 for 736,830.00.
Arteris, Inc. director Joachim Kunkel reported receiving 910 shares of common stock as fully vested restricted stock on January 5, 2026. These shares represent retainer fees that he elected to take in stock instead of cash. The shares were acquired at a stated price of $0.00 per share, reflecting their nature as compensation rather than an open-market purchase. After this grant, Kunkel beneficially owned 68,728 shares of Arteris common stock in direct ownership. He also elected to defer the receipt of the shares, indicating that while the award is fully vested, delivery of the stock is postponed under a deferral arrangement.